Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Corcept Therapeutics Incorporated

35 indications, side-by-side phase, drug & LoA

$82.91

-0.34 (-0.41%)

B 65Pipeline Score Fair Value Pharma · Commercial
Market Cap
6.46 B
EPS
0.45
P/E Ratio
172.06 $
Value Trade
57.04 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    164.90 M

  • R&D Expenses

    66.27 M

  • Operating CF

    -16.77 M

  • Total Assets

    814.88 M

  • Total Liabilities

    176.89 M

  • Equity

    637.99 M

  • D/E Ratio

    12,345

4.84 %
Week
31.95 %
1 Month
77.27 %
3 Month
-19.81 %
6 Month
176.37 %
5 Year
391.59 %
All Time
Cash Data
Healthy

  • Cash Position

    338.18 M

  • Monthly Burn

    5.59 M

  • Runway

    59.2 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Apr 30, 2026
Overview
Volume
719.11 K
52 Week Range
28.66 - 91
% held by Insiders
11.82 %
% held by Institutions
73.84 %
Enterprise Value
6.14 B
Total Shares
106.40 M
Short %
9.54 %
Float Shares
92.14 M
Company Description
HQ: 101 REDWOOD SHORES PARKWAY, RE...
Employees:730
https://www.corcept.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA Date example
Relacorilant Platinum-resistant ovarian cancer
PDUFA
—
Small Molecules
Oncology
Relacorilant Platinum-resistant ovarian cancer
PDUFA
—
Small Molecules
Oncology
Relacorilant Platinum-resistant ovarian cancer
PDUFA
—
Small Molecules
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B65
Pipeline Score
$4.1B
Pipeline Value
Fair Value
Valuation Signal
22
Drugs Scored
2.1x
rNPV / MCap
Top 91%
Small Cap
(rank 82 of 905)
Percentile Rank
Corcept Therapeutics Incorporated holds a solid B-grade pipeline (65/100), with $6.2B risk-adjusted pipeline value, led by Mifepristone in Major Depressive Disorder (Phase 3), across $155B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
mifepristone
Small molecule		Cushing's SyndromePhase 3NCT0093674160% $1.5B COMPLETED 80 - -Sep 1, 2012 -Apr 2, 2014
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
relacorilant
platinum-resistant ovarian cancer
Phase 3
2025-07-14
relacorilant
platinum-resistant ovarian cancer
Phase 3
2025-07-14
relacorilant
platinum-resistant ovarian cancer
Phase 3
2025-07-14
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CORT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CORT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CORT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CORT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CORT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CORT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Corcept Therapeutics Incorporated (CORT) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CORT ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Adrenal Disorders #4 of 6 PHASE 2 relacorilant
NBIX CRNX AZN
—0.95 CONTENDER
ALS #6 of 15 PHASE 2 Dazucorilant
AMLX BIIB IONS
$1.2B 0.91 FOLLOWER
NASH / MASH #7 of 11 PHASE 2 Miricorilant
MDGL NVO LLY
$7.87B 0.92 FOLLOWER
Ovarian Cancer #9 of 61 PHASE 3 Nab-paclitaxel /m^2 + Relacorilant once daily
MRK AZN LLY
$4.0B 0.9 CONTENDER
Endometrial Cancer #13 of 48 PHASE 2 Relacorilant once daily + Nab-paclitaxel /m^2 + Bevacizumab /kg
MRK AZN GILD
$31.09B 0.9 FOLLOWER
Chronic Liver Disease #16 of 27 PHASE 1 Miricorilant
GSK GILD MDGL
$19.9B 0.92 FOLLOWER
Pancreatic Cancer #24 of 73 PHASE 2 Relacorilant once daily + Nab-paclitaxel /m^2 + Gemcitabine /m^2
RVMD RCUS AZN
$3.7B 0.84 FOLLOWER